BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U. C.E.R.A. Maintains Stable Control of Hemoglobin in Patients with Chronic Kidney Disease on Dialysis when Administered Once Every Two Weeks. Am J Nephrol 2008;28:280-9. [DOI: 10.1159/000111115] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Schmidt RJ. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off? Expert Opinion on Pharmacotherapy 2009;10:1509-14. [DOI: 10.1517/14656560902997982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Foley RN. Treatment of anemia in chronic kidney disease: known, unknown, and both. J Blood Med 2011;2:103-12. [PMID: 22287869 DOI: 10.2147/JBM.S13066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Oh J, Joo KW, Chin HJ, Chae DW, Kim SG, Kim SJ, Chung W, Kim S, Huh W, Oh HY, Choi BS, Yang CW, Kim S. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis. J Korean Med Sci 2014;29:76-83. [PMID: 24431909 DOI: 10.3346/jkms.2014.29.1.76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Choy BY, Lam MF, Yip T, Tang HL, Wong PN, Chow CCV, Yap DY, Chan TM. Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients: C.E.R.A. use in Chinese dialysis patients. Nephrology 2013;18:533-8. [DOI: 10.1111/nep.12105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Charytan C. Bundled-Rate Legislation for Medicare Reimbursement for Dialysis Services: Implications for Anemia Management with ESAs. CJASN 2010;5:2355-62. [DOI: 10.2215/cjn.04820610] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
6 Alabdan N, AlRuthia Y, Yates MED, Sales I, Finch CK, Hudson JQ. Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study. PLoS One 2017;12:e0188390. [PMID: 29182650 DOI: 10.1371/journal.pone.0188390] [Reference Citation Analysis]
7 Heidenreich S, Leistikow F, Zinn S, Baumann J, Atzeni A, Bajeski V, Dietzmann J, Dragoun GP; SUPRA Study Group. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study. Clin Drug Investig 2012;32:99-110. [PMID: 22117178 DOI: 10.2165/11594040-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Chanu P, Gieschke R, Charoin JE, Pannier A, Reigner B. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. J Clin Pharmacol 2010;50:507-20. [PMID: 20179322 DOI: 10.1177/0091270009343931] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
9 Kafal AR, Vinh DC, Langelier MJ. Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings. Expert Opinion on Drug Delivery 2018;15:1199-209. [DOI: 10.1080/17425247.2018.1546692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-56. [PMID: 18484803 DOI: 10.2165/00003495-200868080-00009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
11 Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008;9:839-49. [PMID: 18345959 DOI: 10.1517/14656566.9.5.839] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
12 Budde K, Rath T, Kliem V. Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study. J Transplant 2014;2014:179705. [PMID: 24883202 DOI: 10.1155/2014/179705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Locatelli F, Covic A, Eckardt K, Wiecek A, Vanholder R; on behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation 2008;24:348-54. [DOI: 10.1093/ndt/gfn653] [Cited by in Crossref: 129] [Cited by in F6Publishing: 94] [Article Influence: 9.2] [Reference Citation Analysis]
14 Bastos K, Lucarelli LA, De Francesco-Daher E, Filho RP, Henríquez C, Espinoza B, Villanueva I, Schwedt E, Schiavelli R, Correa-Rotter R. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis. Int Urol Nephrol 2013;45:1355-64. [PMID: 22990412 DOI: 10.1007/s11255-012-0272-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Schmid H. Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure. Expert Rev Hematol 2016;9:5-20. [PMID: 26573694 DOI: 10.1586/17474086.2016.1112734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
16 Macdougall IC, Wiecek A, Tucker B, Yaqoob M, Mikhail A, Nowicki M, MacPhee I, Mysliwiec M, Smolenski O, Sułowicz W, Mayo M, Francisco C, Polu KR, Schatz PJ, Duliege AM. Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol 2011;6:2579-86. [PMID: 21940838 DOI: 10.2215/CJN.10831210] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
17 Selby NM, Fonseca SA, Fluck RJ, Taal MW. Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis. Perit Dial Int 2012;32:177-82. [PMID: 22045101 DOI: 10.3747/pdi.2010.00299] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
18 Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 2014;:CD003895. [PMID: 24872328 DOI: 10.1002/14651858.CD003895.pub3] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Pérez-Ruixo JJ, Cucala-Ramos M, García-Gonzalo E, Del Val Romero B, Valveny N. Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis. Br J Clin Pharmacol 2013;75:15-25. [PMID: 22803621 DOI: 10.1111/j.1365-2125.2012.04383.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
20 Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 2017;18:345. [PMID: 29191165 DOI: 10.1186/s12882-017-0688-1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
21 Ohashi N, Sakao Y, Yasuda H, Kato A, Fujigaki Y. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. Int J Nephrol Renovasc Dis 2012;5:53-60. [PMID: 22536082 DOI: 10.2147/IJNRD.S23447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
22 Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2017;8:CD009904. [PMID: 28782299 DOI: 10.1002/14651858.CD009904.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Cano F, Alarcon C, Azocar M, Lizama C, Maria Lillo A, Delucchi A, Gonzalez M, Arellano P, Delgado I, Droguett MT. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol 2011;26:1303-10. [PMID: 21416403 DOI: 10.1007/s00467-011-1846-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
24 Mikhail A, Shrivastava R, Richardson D. Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease. Nephron Clin Pract 2011;118:c101-24. [DOI: 10.1159/000328063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
25 Morikami Y, Fujimori A, Okada S, Kumei M, Mizobuchi N, Sakai M. Comparison of 2-Week Versus 4-Week Dosing Intervals of Epoetin Beta Pegol on Erythropoiesis and Iron Metabolism in Hemodialysis Patients: Dosing Intervals of Epoetin Beta Pegol. Ther Apher Dial 2014;18:414-20. [DOI: 10.1111/1744-9987.12164] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
26 Ulrich Burger H, Beyer U, Abt M. Issues in the assessment of non-inferiority: perspectives drawn from case studies: Assessment of non-inferiority in case studies. Pharmaceut Statist 2011;10:433-9. [DOI: 10.1002/pst.512] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
27 Uriol-Rivera MG, Obrador-Mulet A, Jimenez-Mendoza S, Corral-Baez A, Perianez-Parraga L, Garcia-Alvarez A, de la Prada FJ. Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial. J Hematol 2021;10:255-65. [PMID: 35059087 DOI: 10.14740/jh862] [Reference Citation Analysis]
28 Macdougall IC. Development of Recombinant Erythropoietin and Erythropoietin Analogs. Textbook of Nephro-Endocrinology. Elsevier; 2018. pp. 217-32. [DOI: 10.1016/b978-0-12-803247-3.00013-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Foley RN. Emerging erythropoiesis-stimulating agents. Nat Rev Nephrol 2010;6:218-23. [DOI: 10.1038/nrneph.2010.19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
30 Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, Hattori M, Suzuki T, Morita S, Ashida A, Ito Y, Kuragano T, Komatsu Y, Sakai K, Tsubakihara Y, Tsuruya K, Hayashi T, Hirakata H, Honda H. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-017-0114-y] [Cited by in Crossref: 81] [Cited by in F6Publishing: 20] [Article Influence: 16.2] [Reference Citation Analysis]
31 Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013;73:117-30. [PMID: 23338536 DOI: 10.1007/s40265-012-0002-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
32 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
33 Wu L, Mould DR, Perez Ruixo JJ, Doshi S. Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic model. J Clin Pharmacol 2015;55:1157-66. [PMID: 25907551 DOI: 10.1002/jcph.527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
34 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Reference Citation Analysis]
35 Duman N, Uyanik A, Unsal A, Sezer S, Camsari T, Cirit M, Yilmaz ME, Altun B, Duranay M, Yildiz A, Sahin I, Dogukan A, Ustundag S, Karayaylali I, Kahveci A, Sindel S, Kiykim AA, Yenicerioglu Y, Akbas E, Ozdener F. Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia. Clin Kidney J 2014;7:464-9. [PMID: 25504109 DOI: 10.1093/ckj/sfu079] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Liu WS, Chu DC, Chan HL, Li SY, Liu CK, Yang CY, Chen YW, Lee PC, Lai YT, Lin CC. Fixed dose of long-acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis. Clin Exp Pharmacol Physiol 2016;43:875-82. [PMID: 27385380 DOI: 10.1111/1440-1681.12618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]